Search Results
the disease process, 2 – 6 with median survival times (MSTs) ranging from 270 to 844 days and low rates of recurrence (0% to 22%) 5 , 7 – 10 and metastasis (5% to 24%). 9 – 12 Perioperative morbidity remains generally high, with reported mortality
might have inherently short life spans that could limit their posttransfusion survival. In healthy dogs, similar to the situation in healthy people, erythrocyte life span is largely a function of agedependent erythrocyte destruction. 9,10 Macrophages
basis of currently available literature, median survival time after diagnosis seems to vary widely in cats. In a recent study, 3 median survival time of diabetic cats was 13 months, whereas it was 20 and 29 months in 2 previous investigations. 4
grave prognosis. We observed that certain dogs with metastatic disease lived longer than expected with aggressive treatment; the decision to initiate treatment was often made at the owner's request, despite the poor odds of survival. The purpose of the
,7,13,14 Radiation therapy alone or in combination with cytoreductive surgery is considered to be the most effective form of treatment. 8,9,15–18 Reported median survival times for dogs with intranasal neoplasia treated with radiation therapy range from 7.4 to 47
modalities, including purely palliative treatment, on the survival time of dogs with brain neoplasms. Although corticosteroids and anticonvulsants have been shown to transiently improve clinical signs and tumor-associated secondary complications (ie
. However, numbers of dogs in those studies 1–5 were low (range, 21 to 59 dogs), and the studies 1–5 varied in regard to inclusion and exclusion criteria and methodology for calculating survival times and censoring patients in survival analysis. The
limited on the impact of anesthetic-related variables on overall survival rate in cats undergoing RTS. 3,4,7,10 Patients undergoing RTS pose major challenges for surgeons and anesthesiologists. Both human and feline RTS patients may be anemic, and many
-specific survival times. Our primary null hypothesis was that progression-free and disease-specific survival times would be superior for cats with mammary adenocarcinoma undergoing bilateral mastectomy compared with unilateral mastectomy. Secondary hypotheses were
exclusively been reported as case series, rather than as comparisons between alternative treatments. There are 2 outcome measures that require comparison: duration of survival and quality of life. In addition, the intriguing possibility that 1 treatment method
